Annals of Surgical Oncology

, Volume 17, Issue 2, pp 643–652 | Cite as

Adenoviral Oncolytic Suicide Gene Therapy for a Peritoneal Dissemination Model of Gastric Cancer in Mice

  • Yu Imamura
  • Shinji Ishikawa
  • Nobutaka Sato
  • Ryuichi Karashima
  • Kotaro Hirashima
  • Yukiharu Hiyoshi
  • Youhei Nagai
  • Yoshikatsu Koga
  • Naoko Hayashi
  • Masayuki Watanabe
  • Gen Yamada
  • Hideo Baba
Translational Research and Biomarkers

Abstract

Background

Peritoneal dissemination of gastric cancer is often refractory to systemic therapies. Although adenoviral gene therapy has been reported to be a potentially useful therapeutic modality, the adenovirus itself has a dose-limiting toxicity. A novel system was constructed using adenoviral oncolytic suicide gene therapy targeting carcinoembryonic antigen (CEA), and its therapeutic effect and the possibility to reduce the total viral dose while still preserving the antitumor effect were assessed.

Methods

Three types of adenoviruses were prepared for this novel system: (A) Ad/CEA-Cre, (B) Ad/lox-CD::UPRT for a Cre/loxP system, and (C) Ad/CEA-E1 for conditionally replicating adenovirus. The antitumor effect of the oncolytic suicide gene therapy (A + B + C) was then evaluated in vitro. Mice bearing peritoneal dissemination of human gastric cancer were treated with either this system (A + B + C) or with a tenfold viral dose of suicide gene therapy (A + B). The adverse effects in terms of hepatotoxicity were then evaluated between the two groups.

Results

The current system (A + B + C) demonstrated significantly better cytotoxic effect for CEA-producing cell lines than did suicide gene therapy (A + B) at the same viral dose in vitro. The effect of oncolytic suicide gene therapy was almost equal to that of the tenfold viral dose of suicide gene therapy in vivo. The hepatotoxicity of the two treated groups was also found to be equivalent.

Conclusion

It was possible to reduce the total adenoviral dose of oncolytic suicide gene therapy while still preserving the antitumor effect.

Keywords

Gastric Cancer Green Fluorescent Protein Expression Hepatotoxicity Peritoneal Dissemination MKN45 Cell 

Notes

Acknowledgment

The authors thank Shoko Nakata for valuable technical advice, and Hiroko Taniguchi and Kenichi Iyama for assistance in performing histological examinations.

References

  1. 1.
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1497 cases. Cancer. 1978;41:941–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Yamada E, Miyaishi S, Yamauchi M, et al. The surgical treatment of cancer of the stomach. Int Surg. 1980;65:387–99.PubMedGoogle Scholar
  4. 4.
    Bando E, Yonemura Y, Miwa K, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 1999;178:256–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol. 2006;32:602–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding. Oncology. 2000;58:96–107.CrossRefPubMedGoogle Scholar
  7. 7.
    Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg. 1998;228:347–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Nakajima T, Nishi M, Kajitani T. Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9,700 cases in the Cancer Institute Hospital, Tokyo. Semin Surg Oncol. 1991;7:365–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 1999;86:1657–68.CrossRefPubMedGoogle Scholar
  10. 10.
    Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS. (2001) Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology. 60:24–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Fujimura T, Yonemura Y, Shibata K, et al. Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer. Oncol Rep. 2000;7:809–14.PubMedGoogle Scholar
  12. 12.
    Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Jeung HC, Rha SY, Jang WI, Noh SH, Chung HC. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg. 2002;89:460–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Takei Y, Saga Y, Mizukami H, Takayama T, Ohwada M, Ozawa K, et al. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol Cancer Ther. 2008;7:704–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Fu X, Tao L, Zhang X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther. 2007;14:480–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Yu HK, Ahn JH, Lee HJ, Lee SK, Hong SW, Yoon Y, et al. Expression of human apolipoprotein(a) kringles in colon cancer cells suppresses angiogenesis-dependent tumor growth and peritoneal dissemination. J Gene Med. 2005;7:39–49.CrossRefPubMedGoogle Scholar
  17. 17.
    Miura Y, Ohnami S, Aoki K, et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett. 2005;218:53–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Tanaka F, Tominaga K, Arakawa T, et al. Interleukin-10 gene transfer to peritoneal mesothelial cells suppresses peritoneal dissemination of gastric cancer cells due to a persistently high concentration in the peritoneal cavity. Cancer Gene Ther. 2008;15:51–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Miyagi M, Aoyagi K, Kato S, Shirouzu K. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol. 2007;12:17–24.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsunemitsu Y, Kagawa S, Fujiwara T, et al. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut. 2004;53:554–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1999;6:113–38.CrossRefPubMedGoogle Scholar
  22. 22.
    Lan KH, Kanai F, Omata M, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 1997;57:4279–84.PubMedGoogle Scholar
  23. 23.
    Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the Cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61:6158–62.PubMedGoogle Scholar
  24. 24.
    Kijima T, Osaki T, Kishimoto T, et al. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 1999;59:4906–11.PubMedGoogle Scholar
  25. 25.
    Goto H, Osaki T, Hayashi S, et al. Gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. Int J Cancer. 2001;94:414–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Nishiyama T, Kawamura Y, Sakai T, et al. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res. 1985;45:1753–61.PubMedGoogle Scholar
  27. 27.
    Chung-Faye GA, Chen MJ, Kerr DJ, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001;8:1547–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999;59:2623–8.PubMedGoogle Scholar
  29. 29.
    Sato Y, Tanaka K, Saito I, et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun. 1998;244:455–62.CrossRefPubMedGoogle Scholar
  30. 30.
    Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002;9:979–86.CrossRefPubMedGoogle Scholar
  31. 31.
    Small EJ, Carducci MA, Wilding G, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14:107–17.CrossRefPubMedGoogle Scholar
  32. 32.
    Tanaka T, Huang J, Hamada H, et al. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res. 2006;12:3803–13.CrossRefPubMedGoogle Scholar
  33. 33.
    Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther. 2003;10:388–95.CrossRefPubMedGoogle Scholar
  34. 34.
    Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, et al. Sectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 2003;125:1203–18.CrossRefPubMedGoogle Scholar
  35. 35.
    Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing effect of cancer cells by herpes simplex virus thymidine kinase gene is mediated by conneins. Proc Natl Acad Sci USA. 1996;93:1831–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K. Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol. 2003;23:1309–15.PubMedGoogle Scholar
  37. 37.
    Erbs P, Regulier E, Mehtali M, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60:3813–22.PubMedGoogle Scholar
  38. 38.
    Tomko R, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroups C adenoviruses and subgroup B coxackieviruses. Proc Natl Acad Sci USA. 1997;94:3352–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Miyagawa K, Sakakura C, Otsuji E, et al. Overexpression of RegIV in peritoneal dissemination of gastric cancer and its potential as A novel marker for the detection of peritoneal micrometastasis. Anticancer Res. 2008;28:1169–79.PubMedGoogle Scholar
  40. 40.
    Goldenberg DM, Sharkey RM, Primus FJ. Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst. 1976;57:11–22.PubMedGoogle Scholar
  41. 41.
    Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer. 2007;109:188–97.CrossRefPubMedGoogle Scholar
  42. 42.
    Heideman DA, Snijders PJ, Gerritsen WR, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAMtargeted adenoviral vectors. Cancer Gene Ther. 2001;8:342–51.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Yu Imamura
    • 1
  • Shinji Ishikawa
    • 1
  • Nobutaka Sato
    • 1
  • Ryuichi Karashima
    • 1
  • Kotaro Hirashima
    • 1
  • Yukiharu Hiyoshi
    • 1
  • Youhei Nagai
    • 1
  • Yoshikatsu Koga
    • 1
  • Naoko Hayashi
    • 1
  • Masayuki Watanabe
    • 1
  • Gen Yamada
    • 2
  • Hideo Baba
    • 1
  1. 1.Department of Gastroenterological Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamoto-CityJapan
  2. 2.Center for Animal Resources and Development (CARD), Institute of Molecular Embryology and Genetics, and Global COE “Cell Fate Regulation Research and Education Unit”Kumamoto UniversityKumamoto-CityJapan

Personalised recommendations